Who
Jay M. Moyes
Director
Company insider
Files Form 4 as: Director, BioCardia; Director, Puma Biotechnology; Chief Financial Officer, SiNtx Technologies; Chief Financial Officer, Sera Prognostics; Director, Achieve Life Sciences; Director, Osiris Therapeutics; Chief Financial Officer, Myriad Genetics.
In numbers
- Trades disclosed
- 511
- Buys
- 2
- Sells
- 27
- Bought
- $17K
- Sold
- $8.1M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 10 Feb 2006
- Last trade
- 6 Jul 2026
- Last filed
- 7 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jul 2026filed 7 Jul 2026 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 6 Jul 2026filed 7 Jul 2026 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $159K22,000 at $7.22 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $159K22,000 at $7.22 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SINT SiNtx TechnologiesMedical Devices | SEC FORM 4 Bought | $2,9101,000 at $2.91 | filing |
| 23 Feb 2026filed 25 Feb 2026 | SINT SiNtx TechnologiesMedical Devices | SEC FORM 4 Bought | $2,9101,000 at $2.91 | filing |
| 8 Dec 2025filed 10 Dec 2025 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 26 Aug 2025filed 27 Aug 2025 | SINT SiNtx TechnologiesMedical Devices | SEC FORM 4 Bought | $11K3,000 at $3.59 | filing |
| 13 Jun 2025filed 17 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $75K22,000 at $3.40 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Oct 2024filed 16 Oct 2024 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —829 at $0.00 | filing |
| 18 Jun 2024filed 21 Jun 2024 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $73K22,000 at $3.34 | filing |
| 18 Oct 2023filed 19 Oct 2023 | BCDA BioCardiaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,434 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $76K22,000 at $3.45 | filing |
| 13 Jun 2023filed 15 Jun 2023 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 6 Mar 2023filed 7 Mar 2023 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —51,800 at $0.00 | filing |
| 6 Mar 2023filed 7 Mar 2023 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —32,800 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Contrast: Aurinia Pharmaceuticals (NASDAQ:AUPH) & Puma Biotechnology (NASDAQ:PBYI)PBYI · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Jay M. Moyes; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.